Clinical Trials Browser

Breast Neoplasms

NCT07085767 2026-03-16

OPERA-02

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

Phase 3 Recruiting

3,902 enrolled

Breast

Breast Neoplasms

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

920 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03701334 2026-03-03

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 2 FDA

Breast

Breast Neoplasms

NCT05827081 2026-03-02

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

1,020 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast

Breast Neoplasms

NCT07400523 2026-02-10

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Not yet recruiting

446 enrolled

Breast

Breast Neoplasms

NCT04055493 2025-08-26

ADAPTcycle

Phase 3 Active not recruiting

1,684 enrolled

Breast

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

Phase 3 Active not recruiting

456 enrolled

Breast

Breast Neoplasms

NCT03439046 2024-08-01

BioItaLEE

Phase 3 Completed

287 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

271 enrolled

Breast

Breast Neoplasms

NCT02422615 2023-11-30

MONALEESA-3

Phase 3 Completed

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT02941926 2023-10-24

COMPLEEMENT-1

Phase 3 Completed

3,246 enrolled 11 charts

Breast

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

Phase 3 Completed

41 enrolled

Breast

Breast Neoplasms

NCT03096847 2021-10-11

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Phase 3 Completed

502 enrolled 20 charts

Breast

Breast Neoplasms, Osteitis Deformans

NCT03905343 2021-06-16

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3 Terminated

25 enrolled

Breast

Breast Neoplasms

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3 Terminated

8 enrolled 4 charts

BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

Clinical Trials

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

OPERA-02

NoLEEta

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NATALEE

Adjuvant WIDER

FourLight-3

DISCORDANT

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

ADAPTcycle

HARMONIA

BioItaLEE

Detect V / CHEVENDO (Chemo vs. Endo)

MONALEESA-3

COMPLEEMENT-1

RIBBIT

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib